For instance, a comprehensive study published in Obesity Reviews indicated that without structured dietary and exercise interventions, individuals on GLP-1 medications experienced muscle loss comprising up to nearly half of their total weight loss (Wilding et al., 2021)
However, studies have shown that GLP-1 drugs such as semaglutide may lead to 3040% of the weight loss coming from muscle mass, potentially resulting in reduced metabolic rate and increased risk of weight regain
Your provider will guide expectations based on your health history and treatment plan
CrossRef Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Wafaa Ramadan Ahmed, Khalid Hamid Fadul INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2026;[Epub] CrossRef GIPR:GCGR co-agonism restores normal weight in obese rodents Diego Perez-Tilve, Fa Zhang, Yujin Zhang, Kaitlyn Lohman, Joyce Sorrell, Andrew Vick, Timo D
[DOI] [PubMed] [Google Scholar] Niki E
Decotiis says
